We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Eli Lilly Arthritis Drug Enters Trial as Possible COVID-19 Therapy
Eli Lilly Arthritis Drug Enters Trial as Possible COVID-19 Therapy
Eli Lilly’s arthritis treatment Olumiant (baricitinib) is being investigated as a potential COVID-19 treatment in one arm of a National Institutes for Allergy and Infectious Diseases adaptive trial.